TY - JOUR
T1 - Jet lag
T2 - Clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial
AU - Spitzer, Robert L.
AU - Terman, Michael
AU - Williams, Janet B.W.
AU - Terman, Jiuan Su
AU - Malt, Ulrik F.
AU - Singer, Forbes
AU - Lewy, Alfred J.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1999/9
Y1 - 1999/9
N2 - Objective: The goals of this study were to validate a new rating scale for measuring severity of jet lag and to compare the efficacy of contrasting melatonin regimens to alleviate jet lag. Method: This was a randomized, double-blind trial of placebo and three alternative regimens of melatonin (5.0 mg at bedtime, 0.5 mg at bedtime, and 0.5 mg taken on a shifting schedule) for jet lag. The subjects were 257 Norwegian physicians who had visited New York for 5 days. Jet lag ratings were made on the day of travel from New York back to Oslo (6 hours eastward) and for the next 6 days in Norway. The main outcome measures were scale and item scores from a new, syndrome-specific instrument, the Columbia Jet Lag Scale, that identifies prominent daytime symptoms of jet lag distress. Results: There was a marked increase in total jet lag score in all four treatment groups on the first day at home, followed by progressive improvement over the next 5 days. However, there were no significant group differences or group-by-time interactions. In addition, there was no group effect for sleep onset, time of awakening, hours slept, or hours napping. Ratings on a summary jet lag item were highly correlated with total jet lag scores (from a low of r=0.54 on the day of travel to a high of r=0.80 on day 3). The internal consistency of the total jet lag score was high on each day of the study. Conclusions: The use of melatonin for preventing jet lag needs further study.
AB - Objective: The goals of this study were to validate a new rating scale for measuring severity of jet lag and to compare the efficacy of contrasting melatonin regimens to alleviate jet lag. Method: This was a randomized, double-blind trial of placebo and three alternative regimens of melatonin (5.0 mg at bedtime, 0.5 mg at bedtime, and 0.5 mg taken on a shifting schedule) for jet lag. The subjects were 257 Norwegian physicians who had visited New York for 5 days. Jet lag ratings were made on the day of travel from New York back to Oslo (6 hours eastward) and for the next 6 days in Norway. The main outcome measures were scale and item scores from a new, syndrome-specific instrument, the Columbia Jet Lag Scale, that identifies prominent daytime symptoms of jet lag distress. Results: There was a marked increase in total jet lag score in all four treatment groups on the first day at home, followed by progressive improvement over the next 5 days. However, there were no significant group differences or group-by-time interactions. In addition, there was no group effect for sleep onset, time of awakening, hours slept, or hours napping. Ratings on a summary jet lag item were highly correlated with total jet lag scores (from a low of r=0.54 on the day of travel to a high of r=0.80 on day 3). The internal consistency of the total jet lag score was high on each day of the study. Conclusions: The use of melatonin for preventing jet lag needs further study.
UR - http://www.scopus.com/inward/record.url?scp=0032860720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032860720&partnerID=8YFLogxK
M3 - Article
C2 - 10484950
AN - SCOPUS:0032860720
SN - 0002-953X
VL - 156
SP - 1392
EP - 1396
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 9
ER -